Status:
COMPLETED
AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy
Lead Sponsor:
AstraZeneca
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the efficacy and safety of AZD6244 (ARRY-142886)versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line therapy ...
Eligibility Criteria
Inclusion
- Confirmed with pancreatic cancer
- Have failed first line gemcitabine therapy
Exclusion
- Previous therapy with EGFR inhibitor, MEK inhibitor or capecitabine.
- Any recent surgery, unhealed surgical incision or severe condition such as uncontrolled cardiac disease or chronic gastrointestinal diseases.
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00372944
Start Date
August 1 2006
End Date
October 1 2008
Last Update
August 13 2014
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Alhambra, California, United States
2
Research Site
Bakersfield, California, United States
3
Research Site
Palm Springs, California, United States
4
Research Site
Santa Maria, California, United States